Breast MRI
Risk-Stratified Screening

This activity is designed for medical imaging and healthcare professionals including radiologists, interventional radiologist, and radiologic technologists who diagnose and treat patients with breast disease.
 

	Format:	Online Activity
	MD Credit: MD Fee:	1.0 AMA PRA Category 1 $25
	RT Credit: RT Fee:	1.0 ARRT Category A (certificate accepted by ARMRIT) $10

IMPORTANT NOTICE: Breast MRI: Risk-Stratified Screening expires on August  1st , 2017

If you want credit, the course(s) must be completed (i.e.: view the recording, pass the posttest, AND print the certificate) BEFORE  August 1st.

Course Overview and Educational Objectives

In the United States, breast cancer is the most common non-skin cancer and the second leading cause of cancer-related death in women.[1] Early detection and treatment have been shown to decrease breast cancer mortality. Breast magnetic resonance imaging (MRI) is the most sensitive screening test for breast cancer. MRI detects a significant number of additional breast cancers in intermediate- to high-risk women with dense breasts who have undergone full-field digital mammography supplemented with screening breast ultrasound.[2]

Based on recent evidence on the efficacy of MRI screening in high-risk patients, the American Cancer Society (ACS) has issued guidelines for the early detection of breast cancer that include MRI [3].

1. Source for incidence and mortality data: Surveillance, Epidemiology, and End Results (SEER) Program and the National Center for Health Statistics. Available at http://seer.cancer.gov.
2. Kuhl C, Weigel S, Schrading S, et al. Prospective multicenter cohort study to refine management recommendations for women at elevated familial risk of breast cancer: the EVA trial. J Clin Oncol. 2010 Mar 20;28(9):1450-1457.
3. Saslow D, Boetes C, Burke W, et al. American Cancer Society Breast Cancer Advisory Group. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin. 2007;57(2):75-89.

After completing this educational material, the learner should be able to:

• Discuss the evidence that supports MRI screening for high-risk women
• Differentiate small cancers from normal anatomy on MRI and improve perception of small in situ lesions
• Review the interpretation challenges of breast MRI screening and how to overcome them
• Discuss the future direction of breast MRI screening and probable impact on clinical practice

Tuition
Tuition for this course includes unlimited access to the course and Certificate of Credit.

ICPME accepts American Express, Discover, MasterCard, and Visa. Please note: tuition payments are non-refundable.

ACCME Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and International Center for Postgraduate Medical Education, and RADGOGS. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation
Physicians
The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

SA-CME: This activity meets the criteria for self-assessment toward the purpose of fulfilling requirements in the American Board of Radiology (ABR) Maintenance of Certification Program.

The European Accreditation Council for CME (EACCME®)
The UEMS-EACCME® has mutual recognition agreements with the American Medical Association (AMA) for live events and e-learning materials. For more information, go to http://www.uems.eu/uems-activities/accreditation/eaccme.

Radiologic Technologists
This program has been approved by the American Society of Radiologic Technologists (ASRT) for 1.0 hour of ARRT Category A continuing education credit.

How to Enroll in this Activity
There are no prerequisites for this program. Estimated time to complete this activity is one hour.

• Click ENROLL NOW, then CONTINUE, CONFIRM ORDER, and ACCESS COURSE NOW.
• To access the course content, click on a chapter title below. The course content is accessible from your MY ACCOUNT page until the published expiration date.
• You must review all of the chapters in this activity to receive credit.

How to Receive Credit
Your online account with ICPME serves as a permanent record of credit certificates earned through www.icpme.us

• Log-in to your account at www.icpme.us.
• View the entire activity.
• To complete the POSTTEST and COURSE EVALUATION, click the icons on the left hand side of the page.
• A passing grade of at least 75% is required to receive credit. You may take the test up to three times.
• Upon receipt of a passing grade, click the CERTIFICATE icon to print a credit certificate.

Faculty
Gillian M. Newstead, MD, FACR

Dr. Newstead received her medical degree from the University of Edinburgh in Scotland and completed an internship at Genesee Hospital in Rochester, New York. She then completed a residency in radiology at Strong Memorial Hospital in Rochester and Temple University Hospital in Philadelphia. She is board certified in Radiology by the American College of Radiology.

Dr. Newstead is a member of numerous medical organizations including the American College of Radiology, the Radiological Society of North America, Association for Breast Cancer Control, and the Society for Breast Imaging. She has published more than 50 papers including Radiology, American Journal of Roentgenology, and European Radiology. Dr. Newstead’s awards and honors include election to fellowship status by the American College of Radiology and she was voted as the “Attending of the Year” for excellence in teaching by the residents at the New York University Department of Radiology.

Dr. Newstead’s research interests lie in breast cancer screening and diagnosis and breast MRI. Her work has been supported by grants from the American Cancer Society and the National Cancer Institute.

Faculty have reported the following financial relationship(s) to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Gillian M. Newstead, MD, FACR has received consulting fees from Bayer HealthCare and holds intellectual property rights and/or is a patent holder from Quantitative Image at the University of Chicago.

The following planners and managers have reported NO financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Sharon Cancino
Laura Excell, ND, NP, MS, MA, LPC, NCC
Trace Hutchison, PharmD
Samantha Mattiucci, PharmD
Linda McLean, MS
Victoria Phoenix, BS

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Questions
For questions regarding this program, please contact ICPME:
Email: information@icpmed.com
Phone: 607-257-5860 X10


Jointly Provided by

       

 

This activity is supported in part by an independent educational grant from Bayer HealthCare Pharmaceuticals.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.